D.E. Shaw & Co’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

D.E. Shaw & Co’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-21,700	Closed	-$3.39M	–	4264
2020 Q2	$3.39M	Buy	+21,700	New	+$3.3M	﹤0.01%	1979
2019 Q3	–	Sell	-6,100	Closed	-$576K	–	4076
2019 Q2	$576K	Buy	+6,100	New	+$527K	﹤0.01%	3002
2019 Q1	–	Sell	-20,000	Closed	-$1.12M	–	4015
2018 Q4	$1.12M	Buy	+20,000	New	+$1.22M	﹤0.01%	2578

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

D.E. Shaw & Co's RETA Position: Q3 2023 in Review

D.E. Shaw & Co sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 6,075 shares — an estimated $619K sold.

D.E. Shaw & Co first reported a position in RETA in Q3 2018 and held it in 14 quarters. The position peaked at $12.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

D.E. Shaw & Co reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
D.E. Shaw & Co sold 6,075 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $619K.
D.E. Shaw & Co first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 14 quarters.
D.E. Shaw & Co's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $12.2M in Q4 2022.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.